Manganese for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Manganese for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Manganese is a trace mineral the body needs in small amounts to build bone and cartilage, handle glucose, and protect cells from oxygen damage; it is also sold in multivitamin, joint and greens products. Food usually supplies enough. No trial shows that taking more than food provides does anything measurable, while excess tracks with raised blood pressure, diabetes arising in pregnancy and higher death rates. (Full Review)

Protocol

Standard intake target
1.8–2.3 mg/day total
Adequate Intake 1.8 mg/day women, 2.3 mg/day men; supplemental contribution kept to 1–2 mg/day and the all-source total below 11 mg/day
Best time of day
With a meal
Fasting intake raises absorption; food-bound intake is buffered. No circadian advantage to morning or evening dosing has been demonstrated
Single versus split dosing
Single daily dose
Absorption is capped near 3–5% and the half-life runs 13–37 days, so splitting offers no pharmacokinetic advantage
Time to effect
Repletion of a shortfall
Weeks
Repletion of a documented shortfall takes weeks
Depletion rash
Days
Reversed within days of repletion; plasma cholesterol had not recovered after ten days
Benefit endpoints
No defined onset
No benefit endpoint has a defined onset time

Benefits

Contraindications
  • Chronic cholestatic or cirrhotic liver disease (Child-Pugh Class B or C, portacaval anastomosis, transjugular intrahepatic portosystemic shunt)
  • Biallelic SLC30A10 or SLC39A14 variants, or a family history of inherited hypermanganesemia with dystonia
  • Established parkinsonism, manganism, or a first-degree relative with Parkinson's disease
  • Iron-deficiency anaemia (ferritin below 15 ng/mL, or haemoglobin below 12.0 g/dL in women and 13.0 g/dL in men)
  • Long-term parenteral nutrition with a blood manganese above the laboratory reference range
  • Occupational airborne exposure above 0.02 mg/m³ respirable or 0.1 mg/m³ inhalable manganese
  • Pregnancy where blood manganese already sits in the upper quartile for the assay used
    •
Key Interactions
  • Oral iron salts (ferrous sulfate, ferrous fumarate, ferrous bisglycinate)
  • Levodopa–carbidopa and other dopaminergic agents
  • First-generation and second-generation antipsychotics (haloperidol, risperidone)
  • Tetracycline and fluoroquinolone antibiotics (doxycycline, ciprofloxacin, levofloxacin)
  • Calcium-channel blockers (amlodipine, verapamil, nifedipine)
  • Over-the-counter antacids and mineral products (calcium carbonate, magnesium hydroxide, zinc lozenges)
  • Supplements with additive manganese content (multivitamin and multimineral products, greens and superfood powders, joint formulas containing manganese ascorbate, trace-mineral complexes)
  • High-dose ascorbic acid
  • Other interventions (parenteral nutrition, welding and hobby metalwork, manganese-rich well water)
    •

Risk & Side Effects

  • High: Parkinsonian motor impairment from chronic inhalational overexposure (conflicted); loss of cognitive performance with elevated environmental manganese
    •
  • Medium: Higher gestational diabetes risk at high blood manganese; elevated blood pressure and arterial stiffness in older adults; increased all-cause and cardiovascular mortality at both ends of the range
    •
  • Low: Brain manganese accumulation in chronic liver disease; unintended intake above the Tolerable Upper Intake Level from supplements; reduced iron status from sustained high manganese intake
    •
  • Speculative: Acceleration of cellular senescence
    •

Monitoring

Marker Target Why
Whole blood manganese 4–12 µg/L, targeting the lower half The only direct measure of body burden
Serum ferritin 40–150 ng/mL Low iron multiplies manganese absorption through the shared transporter
Haemoglobin 12.5–15.0 g/dL in women, 14.0–16.0 g/dL in men Detects the anaemia that sustained manganese loading can aggravate
Alanine aminotransferase and aspartate aminotransferase 10–26 U/L in women, 10–30 U/L in men Screens for the liver disease that removes biliary clearance
Gamma-glutamyl transferase and alkaline phosphatase Gamma-glutamyl transferase under 20 U/L; alkaline phosphatase 50–90 U/L The specific cholestatic markers; raised values are a stop signal
Estimated glomerular filtration rate 90 mL/min/1.73 m² or above Contextual rather than causal; manganese is not renally cleared
Glycated haemoglobin 4.8–5.3% Places the individual within the metabolic signals reported on both sides

Cadence: Baseline whole blood manganese, iron panel and liver panel before any supplemental manganese; blood manganese and iron panel repeated at three months and twelve months, then every twelve months; liver enzymes annually, or immediately if any movement, tremor or gait change appears

Qualitative Assessment

  • Handwriting size and speed, which shrink early in manganese-related movement impairment
  • Gait steadiness and arm swing, particularly when turning
  • Fine motor tasks such as buttoning, typing accuracy and instrument playing
  • Facial expressiveness, as reported by others rather than self-assessed
  • Tremor at rest versus with action
  • Sleep quality, mood stability and irritability
  • Subjective cognitive clarity, word-finding and sustained attention
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.